These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37926852)

  • 41. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
    Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
    Front Immunol; 2019; 10():108. PubMed ID: 30778352
    [No Abstract]   [Full Text] [Related]  

  • 42. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
    Zhang X; Yang Z; An Y; Liu Y; Wei Q; Xu F; Yao H; Zhang Z
    World J Surg Oncol; 2022 Mar; 20(1):93. PubMed ID: 35331250
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review.
    Han D; Dong J; Li H; Ma T; Yu W; Song L
    Medicine (Baltimore); 2020 Jan; 99(5):e18701. PubMed ID: 32000374
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
    Guo X; Li W; Hu J; Zhu EC; Su Q
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Lin LL; Lin GF; Luo Q; Chen XQ
    Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
    Yuan Z; Cui H; Wang S; Liang W; Cao B; Song L; Liu G; Huang J; Chen L; Wei B
    Front Oncol; 2023; 13():1103320. PubMed ID: 36776290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis.
    Wang BC; Cao RB; Li PD; Fu C
    Cancer Med; 2019 Oct; 8(13):5969-5978. PubMed ID: 31436392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Cui W; Luo Q; Sun SL; Xu JL; Gu H
    Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis.
    Shi H; Zhang W; Zhang L; Zheng Y; Dong T
    Front Immunol; 2023; 14():1265202. PubMed ID: 37822932
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials.
    Elmakaty I; Abdo R; Elsabagh A; Elsayed A; Malki MI
    Cancer Cell Int; 2023 May; 23(1):90. PubMed ID: 37170090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis.
    Mittal N; Singh S; Mittal R; Kaushal J; Kaushal V
    J Cancer Res Ther; 2022; 18(6):1754-1765. PubMed ID: 36412440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
    Gu L; Khadaroo PA; Su H; Kong L; Chen L; Wang X; Li X; Zhu H; Zhong X; Pan J; Chen M
    BMC Cancer; 2019 Jun; 19(1):559. PubMed ID: 31182049
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
    Chen Y; Liu X; Hu Y; Xia L
    Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
    Wang Y; Zhou S; Yang F; Qi X; Wang X; Guan X; Shen C; Duma N; Vera Aguilera J; Chintakuntlawar A; Price KA; Molina JR; Pagliaro LC; Halfdanarson TR; Grothey A; Markovic SN; Nowakowski GS; Ansell SM; Wang ML
    JAMA Oncol; 2019 Jul; 5(7):1008-1019. PubMed ID: 31021376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.
    Zeng YF; Wei XY; Guo QH; Chen SY; Deng S; Liu ZZ; Gong ZC; Zeng WJ
    Front Immunol; 2023; 14():1168244. PubMed ID: 37122727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.